Dr. Mark Awad, Associate Professor of Medicine at Harvard Medical School and Clinical Director of the Lowe Center for Thoracic Oncology at the Dana-Farber Cancer Institute, shared on X (Twitter):
“We know about targeting RET fusion+ lung cancer. Now out in JCO Precision Oncology, our outstanding medical student Malini Gandhi
shows that cancers with wild-type RET amplification can also be successfully targeted with selpercatinib.”
Full article here: Amplification of Wild-Type RET Represents a Novel Molecular Subtype of Several Cancer Types With Clinical Response to Selpercatinib
Source: Mark Awad / X (Twitter)